BP1 overexpression is associated with adverse prognosis in de novo acute myeloid leukemia. Issue 4 (2nd April 2016)

• Record Type: Journal Article
• Authors: Zhou, Jing-dong; Yang, Jing; Guo, Hong; Deng, Zhao-qun; Wen, Xiang-mei; Yang, Lei; Yin, Jia-yu; Xiao, Gao-fei; Lin, Jiang; Qian, Jun
• Is Part Of: Leukemia & lymphoma. Volume 57:Issue 4(2016:Apr.)
• Page Start: 828
• Page End: 834
• Publication Date: 2016-04-02
• Subjects: Acute myeloid leukemia -- BP1 -- DLX4 -- DLX7 -- expression -- prognosis; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2015.1088648
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: To investigate DLX4 isoforms expression and their clinical significance in acute myeloid leukemia (AML). DLX4 transcript variant 1 ( BP1 ) expression was significantly up-regulated in AML patients compared with normal controls. However, DLX4 transcript variant 2 ( DLX7 ) was significantly down-regulated in AML patients. Both in the overall AML and the non-M3 AML cohorts, those patients with high BP1 expression ( BP1 high ) showed significantly lower rates of complete remission than those with low BP1 expression ( BP1 low ). BP1 high cases had significantly shorter overall survival than BP1 low cases in the overall AML cohort, non-M3 AML, and cytogenetically normal AML (CN-AML). Multivariate analysis confirmed the independent prognostic value of BP1 expression among both the overall AML cohort and non-M3 AML as well as CN-AML patients. However, we did not observe the impact of DLX7 expression on prognosis in AML patients. Our study reveals that BP1 overexpression serves as an independent risk factor in de novo AML patients.